NCT04179760View on ClinicalTrials.gov

Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

August 2, 2022

Study Completion Date

October 26, 2022

Conditions
Dermatitis, Atopic
Interventions
BIOLOGICAL

SCM-AGH

SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).

OTHER

Placebo

Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).

Trial Locations (1)

Unknown

Inha University Hospital, Incheon

All Listed Sponsors
lead

SCM Lifescience Co., LTD.

INDUSTRY

NCT04179760 - Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter